(Probenecid + sulopenem etzadroxil) is under clinical development by Iterum Therapeutics and currently in Pre-Registration for Urinary Tract Infections. According to GlobalData, Pre-Registration drugs for Urinary Tract Infections have a 79% phase transition success rate (PTSR) indication benchmark for progressing into Marketed. GlobalData’s report assesses how (Probenecid + sulopenem etzadroxil)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

(Probenecid + sulopenem etzadroxil) overview

Fixed dose combination of sulopenem etzadroxil and probenecid (sulopenem ) is under development for the treatment of complicated urinary tract infections, uncomplicated urinary tract infections (uUTI), complicated intra-abdominal infections, community-acquired bacterial pneumonia, pelvic inflammatory disease and bacterial infections like acute bacterial prostatitis, gonococcal urethritis. The drug candidate is a penem beta-lactam antibiotic formulated as bilayer tablet administered through oral route. It is a prodrug of sulopenem which acts by targeting penicillin binding protein (PBP).

Iterum Therapeutics overview

Iterum Therapeutics is a clinical-stage pharmaceutical company. It develops anti-infectives for multi-drug resistant (MDR) pathogens for treating serious and life-threatening diseases among others. The company mainly develops sulopenem, an oral and IV targeted-spectrum penem antibiotic for the treatment of infections caused by multi-drug resistant, gram-negative bacteria in both the hospital and community environments. Iterum Therapeutics seeks to work in partnership with other pharmaceutical companies for product development and commercialization opportunities. The company has operations with research and development facility in the US. Iterum Therapeutics is headquartered in Dublin, Ireland.

For a complete picture of (Probenecid + sulopenem etzadroxil)’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.